Journal: eLife

Article Title: Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1 + TAMs

doi: 10.7554/eLife.103016

Figure Lengend Snippet: ( A ) Gene Set Enrichment Analysis (GSEA) identified GLUT1 and C5aR1 as two top hits related to selective serotonin reuptake inhibitor (SSRI)-induced gene changes. ( B ) GSEA of hepatocellular carcinoma (HCC) RNA-seq data (TCGA cohort) with the SSRI-related gene signature. Sample grouping was made based on the median expression of C5aR1. ( C ) Representative immunohistochemical images showed the expression pattern and cellular distribution of C5aR1 in human HCC tissues. Scale bar, 50 μm. ( D ) Single-cell RNA sequencing analysis showed the expression pattern of C5aR1 with the immune microenvironment of HCC. ( E ) Co-immunofluorescence of C5aR1 (green) with CD163 (red) in HCC samples. Scale bar, 10 μm. ( F ) The drug affinity responsive target stability (DARTS) assay and immunoblot analysis showed C5aR1 protein stability against 5 μg/ml pronase in the presence and absence of 100 μM citalopram treatment. ( G ) The DARTS assay and immunoblot analysis showed C5aR1 protein stability against 5 μg/ml pronase in the presence of different concentrations of citalopram treatment. ( H ) The overall conformation of citalopram binding to C5aR1. ( I ) Representative models of citalopram in pose-1 (left), pose-2 (middle), and allosteric site (right). Several polar interactions were indicated by black dashed lines. ( J ) HEK293T cells were transfected with either WT or mutant C5aR1 expression plasmids for 48 hr, followed by DARTS assay with immunoblotting analysis of C5aR1 protein levels. In all panels, *p < 0.05, **p < 0.01. Values as mean ± SD and compared by the Student’s t test ( F ) or one-way analysis of variance (ANOVA) multiple comparisons with Tukey’s method among groups ( G, J ). Figure 2—source data 1. Original western blots for , indicating the relevant bands and treatments. Figure 2—source data 2. Original files for western blot analysis displayed in .

Article Snippet: The following antibodies were used: C5aR1 (1:50, Proteintech, 10375-1-AP) and CD163 (1:200, Abcam, ab182422).

Techniques: RNA Sequencing, Expressing, Immunohistochemical staining, Single Cell, Immunofluorescence, Western Blot, Binding Assay, Transfection, Mutagenesis

Journal: eLife

Article Title: Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1 + TAMs

doi: 10.7554/eLife.103016

Figure Lengend Snippet: ( A ) Uniform Manifold Approximation and Projection (UMAP) of SMART-seq2-based single CD45 + cells. The tSNE (by cluster) was acquired from http://cancer-pku.cn:3838/HCC/ . ( B ) The UMAP showing C5AR1 expression in HCC immune cell clusters. ( C ) Violin plot showing C5AR1 expression in different immune cell clusters.

Article Snippet: The following antibodies were used: C5aR1 (1:50, Proteintech, 10375-1-AP) and CD163 (1:200, Abcam, ab182422).

Techniques: Expressing

Journal: eLife

Article Title: Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1 + TAMs

doi: 10.7554/eLife.103016

Figure Lengend Snippet: ( A ) The drug affinity responsive target stability (DARTS) assay and immunoblot analysis showed C5aR1 protein stability against 5 μg/ml pronase in the presence of different concentrations of selective serotonin reuptake inhibitors (SSRIs) treatment (0, 1, 10, 50, and 100 μM). ( B ) For C5aR1, the predicted binding energy distribution of the clusters with poses more than 50. ( C ) Sequencing analysis showed the successful generation of six C5aR1 mutants. ( D ) The best-scored complex models of C5aR1 with other four different SSRIs. ( E ) HEK293T cells were transfected with either WT or mutant C5aR1 (D282A) expression plasmids for 48 hr, followed by DARTS assay with immunoblotting analysis of C5aR1 protein levels. In all panels, *p < 0.05, **p < 0.01. Values are presented as mean ± SD and compared by one-way analysis of variance (ANOVA) multiple comparisons with Tukey’s method among groups ( E ). Figure 2—figure supplement 2—source data 1. Original western blots for , indicating the relevant bands and treatments. Figure 2—figure supplement 2—source data 2. Original files for western blot analysis displayed in .

Article Snippet: The following antibodies were used: C5aR1 (1:50, Proteintech, 10375-1-AP) and CD163 (1:200, Abcam, ab182422).

Techniques: Western Blot, Binding Assay, Sequencing, Transfection, Mutagenesis, Expressing

Journal: eLife

Article Title: Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1 + TAMs

doi: 10.7554/eLife.103016

Figure Lengend Snippet: ( A ) Western blotting showed the knockdown efficiency of GLUT1 in mouse Hepa1-6 cells. ( B ) GLUT1 KD Hepa1-6 cells were subcutaneously injected into the Rag1 −/− or immunocompetent C57BL/6 mice, and mice were treated with 5 mg/kg citalopram when bore visible tumors; 3 weeks later, tumor burden was examined ( n = 6–7 per group). ( C ) The growth kinetics of GLUT1 KD Hepa1-6 tumors in C5ar1 +/− and C5ar1 −/− C57BL/6 host ( n = 7). ( D ) Immunofluorescence analysis of C5a deposition in GLUT1 KD Hepa1-6 tumors from C5ar1 +/− and C5ar1 −/− C57BL/6 host. Scale bar, 50 μm. ( E ) Experimental design of bone marrow transfer experiments. ( F, G, I ) GLUT1 KD Hepa1-6 cells were subcutaneously implanted into syngeneic recipient (r) mice that had been reconstituted with bone marrow cells from either C5ar1 +/− or C5ar1 −/− donor mice. The therapeutic effect of citalopram ( F ), C5a deposition ( G ), and macrophage phagocytosis ( I ) in this model was analyzed. Scale bar, 50 μm. ( H ) The phagocytic capacity of macrophages isolated from GLUT1 KD Hepa1-6 tumors in C5ar1 +/− and C5ar1 −/− C57BL/6 host. Flow cytometry showed the infiltration of CD45 + CD11b + F4/80 + macrophages ( J ), CD206 + TAMs and CD11b + TAMs ( K ), tumor-infiltrating lymphocytes ( L ) in tumor tissues from orthotopic xenograft model, which was generated in immunocompetent C57BL/6 mice with Hepa1-6 cells ( n = 5 per group). ( M, N ) Measurement of CD8 + T cell function in tumor tissues from the groups mentioned in C and F . ( O ) The growth kinetics of GLUT1 KD Hepa1-6 tumors in C5ar1 +/− and C5ar1 −/− C57BL/6 host upon CD8 + T cell depletion ( n = 7). ( P ) Correlation analysis of C5aR1 expression and immune checkpoint molecules, gene signatures of TAMs, exhausted T cells, and effector Tregs in the TCGA cohort ( n = 371). In all panels, *p < 0.05, **p < 0.01, ***p < 0.001; ns, non-significant. Values are presented as mean ± SD and compared by two-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons ( B, C, F, O ), Student’s t test ( H–M ), one-way ANOVA multiple comparisons with Tukey’s method ( B, N ), and the Spearman’s rank correlation methods ( P ). Figure 3—source data 1. Original western blots for , indicating the relevant bands. Figure 3—source data 2. Original files for western blot analysis displayed in .

Article Snippet: The following antibodies were used: C5aR1 (1:50, Proteintech, 10375-1-AP) and CD163 (1:200, Abcam, ab182422).

Techniques: Western Blot, Knockdown, Injection, Immunofluorescence, Isolation, Flow Cytometry, Generated, Cell Function Assay, Expressing

Journal: eLife

Article Title: Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1 + TAMs

doi: 10.7554/eLife.103016

Figure Lengend Snippet: ( A ) Gene Set Enrichment Analysis (GSEA) plot of phagocytosis pathway in macrophages derived from C5ar1 −/− mice and C5ar1 +/− mice. ( B ) Western blotting and immunofluorescence analysis showed C5aR1 protein levels in Cas9-sgControl, -sg C5ar1 THP-1 subclones. ( C ) Effects of C5aR1 deficiency on the macrophage phagocytosis of HCC-LM3 in the presence or absence of C5a stimulation. ( D ) Effects of different selective serotonin reuptake inhibitors (SSRIs) on the macrophage phagocytosis of HCC-LM3 in the presence of C5a stimulation. ( E ) Reconstituted expression of WT and D282A mutant C5aR1 in C5aR1 KO THP-1 cells. ( F ) The effects of citalopram on macrophage phagocytosis in the absence of C5aR1 with reconstituted expression of C5aR1 WT or C5aR1 D282A . In all panels, *p < 0.05, **p < 0.01, ***p < 0.001. Values are presented as mean ± SD and compared by one-way analysis of variance (ANOVA) multiple comparisons with Tukey’s method among groups. Data are representative of three independent experiments ( C, D, F ). Figure 3—figure supplement 2—source data 1. Original western blots for , indicating the relevant bands. Figure 3—figure supplement 2—source data 2. Original files for western blot analysis displayed in .

Article Snippet: The following antibodies were used: C5aR1 (1:50, Proteintech, 10375-1-AP) and CD163 (1:200, Abcam, ab182422).

Techniques: Derivative Assay, Western Blot, Immunofluorescence, Expressing, Mutagenesis

Journal: eLife

Article Title: Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1 + TAMs

doi: 10.7554/eLife.103016

Figure Lengend Snippet: ( A ) Conformations of orthosteric binding sites in human (light blue) and mouse (orange) C5aR1. The conformation of human C5aR1 was obtained from the crystal structure (PDB id: 6c1q). The structure of mouse C5aR1 was predicted using the ColabFold (AlphaFold2) software. ( B ) The predicted binding modes of citalopram to human (light blue) and mouse (orange) C5aR1. The conformations of citalopram were shown in pink (binding mode 1) or deep green (binding mode 2) sticks. For mouse C5aR1, green sticks indicate residues set to flexible in the molecular docking process.

Article Snippet: The following antibodies were used: C5aR1 (1:50, Proteintech, 10375-1-AP) and CD163 (1:200, Abcam, ab182422).

Techniques: Binding Assay, Software

Journal: eLife

Article Title: Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1 + TAMs

doi: 10.7554/eLife.103016

Figure Lengend Snippet: Model depicting the molecular mechanism by which citalopram inhibits the Warburg effect and promotes an anti-tumor response in hepatocellular carcinoma (HCC). In the primary HCC microenvironment (left panel), C5aR1-expressing tumor-associated macrophages (TAMs) exhibit reduced phagocytic capacity and an anti-inflammatory state, which correlates with diminished CD8 + T cell anti-tumor immunity and HCC progression. Upon treatment with citalopram (right panel), the drug not only inhibits the glycolytic metabolism of cancer cells by targeting GLUT1 but also acts on C5aR1 expressed by TAMs, thereby enhancing macrophage-driven anti-tumor immunity. Additionally, citalopram induces a systemic immunostimulatory effect on CD8 + T cell functions through yet-to-be-identified serotonergic mechanisms. The dotted line indicates a causal relationship that has not been fully established through direct evidence.

Article Snippet: The following antibodies were used: C5aR1 (1:50, Proteintech, 10375-1-AP) and CD163 (1:200, Abcam, ab182422).

Techniques: Expressing

Journal: PLoS ONE

Article Title: Nanoparticulate matter exposure results in neuroinflammatory changes in the corpus callosum

doi: 10.1371/journal.pone.0206934

Figure Lengend Snippet: (A) Filtered air (n = 8) or nPM (n = 8) exposed mice stained for C5 (red) in the corpus callosum. Nuclei (DAPI) are stained in blue (400x). (B) Low magnification representation of region analyzed. (C) C5 immunostaining in the corpus callosum was significantly higher in nPM exposed animals compared to the filtered air group (p = 0.001). (D) Filtered air (n = 8) and nPM (n = 8) exposed mice stained for C5α (red) in the corpus callosum. Nuclei (DAPI) are stained in blue (400x). (E) Low magnification representation of region analyzed. (F) C5α immunostaining in the corpus callosum of nPM exposed animals was significantly greater than in the filtered air group (p = 0.02). (G) Filtered air (n = 18) and nPM (n = 18) exposed mice stained for CD88 (red) in the corpus callosum. Nuclei (DAPI) are stained in blue (200x). (H) Low magnification representation of region analyzed. (I) CD88 immunostaining in the corpus callosum was significantly higher in nPM exposed animals compared to the filtered air group (p = 0.04). * signifies p< 0.05, ** signifies p ≤ 0.001. Error bars represent standard deviation. Scale bars indicate 50 μm.

Article Snippet: Slides were incubated overnight with anti-C5 (mouse 1:50 Hycult Biotech, Netherlands; clone BB5.1), anti-CD88 (rat 1:200 Hycult Biotech, Netherland; HM1076) or rabbit complement component C5α (125kDa) antibody (1:50 Santa Cruz, SC-21941).

Techniques: Staining, Immunostaining, Standard Deviation

Journal: The Journal of Neuroscience

Article Title: The Complement Receptor C5aR Controls Acute Inflammation and Astrogliosis following Spinal Cord Injury

doi: 10.1523/JNEUROSCI.5218-14.2015

Figure Lengend Snippet: Production of C5a and expression of C5aR in the injured spinal cord. A, C5a protein concentration in injured WT spinal cord is significantly increased compared with both naive (time point 0) and sham levels at 2 h, 6 h, 12 h, 1 d, 4 d, and 7 d after SCI (n = 4 or 5 per time point, two-way ANOVA with Newman–Keuls post hoc tests). *p < 0.05. **p < 0.01. ****p < 0.0001. B, WT C5a levels are also increased in the plasma in response to SCI, exceeding levels observed in sham-operated mice at 30 min, 2 h, 6 h, 12 h, and 1 d after injury (n = 4 or 5 per time point, two-way ANOVA with Newman–Keuls post hoc tests). *p < 0.05. **p < 0.01. ***p < 0.001. C–E, Representative confocal images showing C5aR expression in the injured spinal cord at 1 and 7 d after injury. C, At 1 d after injury, C5aR appeared present at the lesion epicenter on nucleated Iba1+ cells (arrow) as well as numerous smaller circular/ovoid cells that did not express Iba1 (arrowheads). Scale bar, 6.0 μm. D, At 7 d after injury, C5aR is present on cells with amoeboid morphology in WT mice, which appear to be clustered Iba1+ macrophages/microglia (arrow). Scale bar, 10 μm. E, C5aR expression was also observed on more elongated GFAP+ astrocytes (arrows), alongside C5aR+GFAP− cells with macrophage-like morphology (arrowhead). Scale bar, 13 μm. F, Only a very low level of nonspecific background fluorescence was observed following C5aR staining of lesioned C5ar−/− spinal cord tissue. Scale bar, 35 μm. G, Representative Western blots demonstrating C5aR expression by astrocytes in vitro. Left and middle lanes contain WT and C5ar−/− whole mouse brain homogenates, respectively. Right lane contains protein sample from cultured WT astrocytes.

Article Snippet: Rat anti-C5aR antibody (clone 10/92; 1:1000; Hycult Biotech, #HM1077), in combination with goat anti-rat IgG IRDye-700CW (1:10,000; LI-COR, #926-32219), was used to detect C5aR using similar procedures as detailed above.

Techniques: Expressing, Protein Concentration, Fluorescence, Staining, Western Blot, In Vitro, Cell Culture

Journal: The Journal of Neuroscience

Article Title: The Complement Receptor C5aR Controls Acute Inflammation and Astrogliosis following Spinal Cord Injury

doi: 10.1523/JNEUROSCI.5218-14.2015

Figure Lengend Snippet: C5ar−/− mice have a dual phenotype after SCI. A, BMS locomotor scoring revealed that C5ar−/− mice have significantly improved hindlimb motor function at 7 d after injury compared with WT mice. This trend reversed with time such that, at 28 and 35 d after SCI, WT mice had regained significantly more motor function than C5ar−/− mice (two-way ANOVA with Bonferroni post hoc tests, n = 8–12). B, Pooled BMS scores for individual mice from various experiments at 7 d after injury (Student's two-sided t test, n = 18–21). C, Graph showing the BMS scores for individual mice at 35 d after injury from longitudinal scores plotted in A (Student's two-sided t test, n = 8–12). D, Postmortem T2*-weighted MRI images showing lesion sites in WT and C5ar−/− mice. Scale bar (top left image): coronal images, 400 μm; sagittal images, 1 mm. E, Quantitative analysis revealed significantly larger lesion core volumes in C5ar−/− mice. Representative reconstructions of lesion cores for each genotype are shown in gray. F, G, A reduction in myelin content was observed in C5ar−/− mice at 35 d after SCI (Student's two-sided t test, n = 8 per group). Scale bar: F (top left image), 200 μm. H, I, Reductions in the proportional area (H) and intensity (I) of GFAP staining were also observed in C5ar−/− mice (Student's two-sided t tests, n = 8 per group). J, K, A more widespread presence of Ly6b.2+ cells (J) and CD3+ T cells (K) was observed in C5ar−/− mice at 35 d after injury (two-way ANOVA with Newman–Keuls post hoc tests, n = 5 per group), as also confirmed by area under the curve analysis (Student's two-sided t test, n = 5 per group). *p < 0.05. **p < 0.01. ***p < 0.001. ****p < 0.0001.

Article Snippet: Rat anti-C5aR antibody (clone 10/92; 1:1000; Hycult Biotech, #HM1077), in combination with goat anti-rat IgG IRDye-700CW (1:10,000; LI-COR, #926-32219), was used to detect C5aR using similar procedures as detailed above.

Techniques: Staining

Journal: The Journal of Neuroscience

Article Title: The Complement Receptor C5aR Controls Acute Inflammation and Astrogliosis following Spinal Cord Injury

doi: 10.1523/JNEUROSCI.5218-14.2015

Figure Lengend Snippet: Acute, but not sustained, antagonism of C5aR improves SCI outcomes in Macgreen mice. A, BMS locomotor scores of mice treated with a C5aR antagonist (C5aR-A) for 7 d after SCI have significantly higher BMS scores than vehicle (Veh)-treated mice at 21, 28, and 35 d after injury. *p < 0.05 (two-way ANOVA with Bonferroni post hoc tests, n = 8–10). B, A scatter plot depicting the BMS scores of individual mice at 35 d after SCI. *p = 0.029 (Student's two-tailed t test, n = 8–10). C, D, Data from the ledged tapered beam walk task also indicated that C5aR blockade during the acute period improved long-term recovery, with C5aR-A-treated mice making significantly fewer stepping mistakes (C), and also traversing the beam faster (D) than vehicle-treated SCI controls. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (one-way ANOVA with Newman–Keuls post hoc tests, n = 6–10). E, F, (Sub)acute C5aR-A treatment resulted in significantly more myelin being present at the lesion epicenter at 35 d after SCI compared with vehicle-treated mice. **p = 0.0088 (Student's t test, n = 5 per group). Scale bar: E (top left), 200 μm. E, G, The GFP+ infiltrate in the lesion core of Macgreen mice was also significantly reduced following the C5aR-A treatment regimen. **p = 0.0061 (Student's two-sided t test, n = 5 per group). H–J, GFAP immunoreactivity at 35 d after SCI was not significantly different between treatment groups based on analysis of both proportional area (I) and staining intensity (J). Scale bar: H (top left), 200 μm. K, Improved recovery from SCI was not sustained with continued C5aR-A administration. *p < 0.05, C5ar−/− + vehicle versus WT + vehicle (two-way ANOVA with Bonferroni post hoc tests, n = 4 or 5).

Article Snippet: Rat anti-C5aR antibody (clone 10/92; 1:1000; Hycult Biotech, #HM1077), in combination with goat anti-rat IgG IRDye-700CW (1:10,000; LI-COR, #926-32219), was used to detect C5aR using similar procedures as detailed above.

Techniques: Two Tailed Test, Staining

Journal: The Journal of Neuroscience

Article Title: The Complement Receptor C5aR Controls Acute Inflammation and Astrogliosis following Spinal Cord Injury

doi: 10.1523/JNEUROSCI.5218-14.2015

Figure Lengend Snippet: Inflammation in the (sub)acute period of SCI is reduced with C5aR elimination. A–F, Levels of MCP-1 (A), TNF (B), CXCL1 (C), IL-6 (D), IL-1β (E), and IL-10 (F) were all significantly increased at 12 h after SCI compared with sham-operated controls, regardless of genotype. C5aR deficiency did, however, result in significant reductions in CXCL1, IL-6, and IL-1β in the injured spinal cord compared with WT mice. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (two-way ANOVA with Newman–Keuls post hoc tests, n = 4 or 5). G, H, No significant differences in the Ly6b.2+ inflammatory cell infiltrate were observed between WT and C5ar−/− mice at 1 d (G) and 7 d (H) after SCI. Scale bar: G (bottom image), 40 μm. I, A significant reduction in the number of inflammatory monocytes/macrophages was observed in injured C5ar−/− spinal cord at 7 d after SCI. **p < 0.01 (Student's two-sided t test). n = 5 per group.

Article Snippet: Rat anti-C5aR antibody (clone 10/92; 1:1000; Hycult Biotech, #HM1077), in combination with goat anti-rat IgG IRDye-700CW (1:10,000; LI-COR, #926-32219), was used to detect C5aR using similar procedures as detailed above.

Techniques:

Journal: The Journal of Neuroscience

Article Title: The Complement Receptor C5aR Controls Acute Inflammation and Astrogliosis following Spinal Cord Injury

doi: 10.1523/JNEUROSCI.5218-14.2015

Figure Lengend Snippet: C5aR deficiency in the peripheral immune compartment does not alter the outcome from SCI. A, Flow cytometry data showing chimerization efficacy. [C5ar−/− → WT] BM chimeras (i.e., WT mice that received a C5ar−/− bone marrow transplant) only express background levels of C5aR on circulating granulocytes, equivalent to the amount of nonspecific staining observed on C5ar−/− cells. ***p < 0.001 (one-way ANOVA with Newman–Keuls post hoc). n = 3–7. B, BMS locomotor scoring revealed no significant differences in functional recovery as a result of select C5aR deficiency in the peripheral immune compartment compared with [WT → WT] controls (two-way ANOVA with Bonferroni post hoc tests; n = 6 or 7). C, Scatter plot showing main BMS scores for individual mice at 35 d after SCI. D, No difference was observed between the experimental groups in the amount of myelin within the ventrolateral white matter at 35 d after SCI (Student's two-sided t test, p > 0.05; n = 6 or 7). Scale bar: D (top), 200 μm. E–G, Quantification of the inflammatory infiltrate also showed no differences between the experimental groups in the number of Ly6b.2+ cells (E), the proportional area of CD11b+ immunoreactivity (F), and the number of CD3+ lymphocytes (G) present at the lesion epicenter (Student's two-sided t tests, p > 0.05; n = 6 or 7).

Article Snippet: Rat anti-C5aR antibody (clone 10/92; 1:1000; Hycult Biotech, #HM1077), in combination with goat anti-rat IgG IRDye-700CW (1:10,000; LI-COR, #926-32219), was used to detect C5aR using similar procedures as detailed above.

Techniques: Flow Cytometry, Staining, Functional Assay

Journal: The Journal of Neuroscience

Article Title: The Complement Receptor C5aR Controls Acute Inflammation and Astrogliosis following Spinal Cord Injury

doi: 10.1523/JNEUROSCI.5218-14.2015

Figure Lengend Snippet: Signaling through the C5a-C5aR axis promotes astrocyte proliferation in vivo and in vitro. A, Quantification of BrdU+GFAP+ astrocytes at the lesion site of WT SCI mice that were chronically administered C5aR-A (orange) or vehicle (Veh, blue) solution, and vehicle-treated C5ar−/− mice (red). Note the significantly reduced presence of newly generated astrocytes along the rostral and caudal margins of the lesion in the absence of C5aR signaling (two-way ANOVA with Newman–Keuls post hoc tests; n = 4 or 5 per group). *p < 0.05. **p < 0.01. B, A significant, negative correlation was observed between the total number of BrdU+GFAP+ cells and lesion volumes (Pearson's correlation, p < 0.0001). C, C5a stimulates the proliferation of WT astrocytes in vitro in a dose-dependent manner at concentrations >10 nm (one-way ANOVA with Newman–Keuls post hoc tests). *p < 0.05. ***p < 0.001. Graph is representative of three experimental repeats. D, C5ar−/− astrocytes did not proliferate in response to high-dose C5a (50 nm; Student's two-sided t test, p > 0.05). E, Exposure of cultured astrocytes to C5a (50 nm) resulted in a significant increase in the ratio of P-STAT3 to STAT3. Addition of the STAT3 Inhibitor BP-1-102 (10 μm) just before C5a stimulation blocked this increase in STAT3 phosphorylation (one-way ANOVA with Newman–Keuls post hoc tests). **p < 0.01. F, Stimulation of C5ar−/− astrocytes with 50 nm of C5a did not lead to a significant change in STAT3 phosphorylation (Student's two-sided t test, p > 0.05). G, Addition of BP-1-102 (5 μm) blocked C5a-induced astrocyte proliferation in vitro (one-way ANOVA with Newman–Keuls post hoc tests). **p < 0.01. ***p < 0.001. Dotted line indicates the initial number of cells plated. D–F, Data are mean ± SEM, with n = 6 biological replicates. ns, Not significant.

Article Snippet: Rat anti-C5aR antibody (clone 10/92; 1:1000; Hycult Biotech, #HM1077), in combination with goat anti-rat IgG IRDye-700CW (1:10,000; LI-COR, #926-32219), was used to detect C5aR using similar procedures as detailed above.

Techniques: In Vivo, In Vitro, Generated, Cell Culture

Journal: The Journal of Neuroscience

Article Title: The Complement Receptor C5aR Controls Acute Inflammation and Astrogliosis following Spinal Cord Injury

doi: 10.1523/JNEUROSCI.5218-14.2015

Figure Lengend Snippet: Diagram showing the proposed dual and time-dependent role of C5aR in SCI. In the (sub)acute period (0–7 d after SCI), activated astrocytes and microglia proliferate and/or migrate to the site of injury. Activation of these cells occurs in part through increased C5a levels as a result of complement activation, which in turn augments their production and release of inflammatory cytokines at the lesion site. Release of CXCL1 is a key signal for neutrophil recruitment to the site of SCI. IL-1β and IL-6 aid in the recruitment of blood monocytes and macrophages, which promote secondary injury if adopting an M1 phenotype. In the postacute to chronic period of SCI (7 d after SCI onwards), C5aR signaling is critically required for STAT3-mediated astrocyte proliferation and glial scar formation, which seals the injury site and prevents the spread of secondary injury. Through its regulation of IL-6 levels, C5aR may also be involved IL-6R-dependent astrocyte proliferation. 1(Anderson et al., 2004, 2005; Nguyen et al., 2008); 2(Lacy et al., 1995; Griffin et al., 2007; Ager et al., 2010); 3(Gasque et al., 1995; Lacy et al., 1995; Woodruff et al., 2008); 4(Acarin et al., 2000; Pineau and Lacroix, 2007; Pineau et al., 2010); 5(Klusman and Schwab, 1997; Romano et al., 1997; Dinarello, 2009); 6(Baggiolini and Clark-Lewis, 1992; Harada et al., 1994; Taub et al., 1996); 7(Gensel et al., 2009; Kigerl et al., 2009; Blomster et al., 2013a); 8(Gensel et al., 2009; Shechter et al., 2009, 2013); 9(Okada et al., 2006); and 10(Bush et al., 1999; Faulkner et al., 2004; Okada et al., 2006; Herrmann et al., 2008; Wanner et al., 2013).

Article Snippet: Rat anti-C5aR antibody (clone 10/92; 1:1000; Hycult Biotech, #HM1077), in combination with goat anti-rat IgG IRDye-700CW (1:10,000; LI-COR, #926-32219), was used to detect C5aR using similar procedures as detailed above.

Techniques: Activation Assay

Journal: Nature Communications

Article Title: Schwann cell C5aR1 co-opts inflammasome NLRP1 to sustain pain in a mouse model of endometriosis

doi: 10.1038/s41467-024-54486-6

Figure Lengend Snippet: Representative images of SOX10 and C5aR1 (#orb393229, rabbit polyclonal, Biorbyt Ltd, 1:100) co-expression in sciatic ( a ) and trigeminal ( b ) nerve tissue from C57BL/6 J female (B6) mice, ( n = 4 independent experiments) (Scale bar, 50 μm). (c) C5aR1 mRNA relative expression in primary mouse and human Schwann cells ( n = 3 independent experiments). d Schematic representation of AAV-(loxP-shRNA)- C5aR1 vector pre- and post-Cre switch. e Representative images and cumulative data (Rcoloc) of SOX10 and C5aR1 (#orb393229, rabbit polyclonal, Biorbyt Ltd, 1:100) co-expression in sciatic and trigeminal nerve tissue in Plp -AAV- C5aR1 and Control mice ( n = 4 independent experiments) (Scale bar, 50 μm). f Time-dependent periorbital (PMA), hind paw (HMA), and abdominal (AMA) mechanical allodynia in endometriotic (endo) or Sham Plp -AAV- C5aR1 and Control mice. ( n = 8 mice per group). g Representative images and cumulative data of F4/80 + cells in sciatic and trigeminal nerve tissue in endo or Sham Plp -AAV- C5aR1 and Control mice. ( n = 4 independent experiments) (Scale bar, 50 μm, dashed lines, perineurium ). h Representative images and cumulative data of transmigrated macrophages after stimulation of human and mouse Schwann cells with C5a or vehicle (Veh) and in the presence of DF2593A (DF25) or Veh ( n = 6 independent experiments). Data are mean ± s.e.m. c , Student’s t-test, f , 2-way, g, h 1-way ANOVA, Bonferroni correction; **** P < 0.0001 vs. Sham/Control, #### P < 0.0001 vs. Endo/Control. Source data are provided as a Source Data file.

Article Snippet: Cells were transfected with plasmid DNA (2 µg) expressing murine C5aR1 (#MR223830, Origene), Nlrp1a (#MR221045, Origene), Nlrp1b (#MR215179, Origene) and Nlrp3 (#75127, Addgene) genes using jetOPTIMUS® DNA transfection reagent (#55-250; Polyplus, Lexington, MA, USA) and incubated for 24 h before immunofluorescence.

Techniques: Expressing, shRNA, Plasmid Preparation, Control